医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

新型コロナウイルス感染症の流行拡大が長く続き、これに伴ううつ病を解消する努力がペットにまで広がっている。散歩させるのが困難になったペットの情緒的な憂うつ感を減らし、家でも健康でいられるように世話するための製品が注目されている。…　続きを読む

ith the COVID-19 pandemic showing no sign of abating, a lot of people are suffering from depressions. The situation is no better for pets that have to stay home most of the time. Several useful products are out on the market that can relieve the stress of the companion animals unable to go out as much as before.…　続きを読む

r. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Fluphenazine Hydrochloride Tablets, USP, a therapeutic equivalent generic version of Prolixin Tablets, 1 mg, 2.5 mg, 5 mg, and 10 mg, approved by the U.S. Food and Drug Administration (USFDA).…　続きを読む

oston Immune Technologies and Therapeutics, Inc. (BITT), a privately held developer of novel antagonist antibodies for cancer and other diseases, and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that they have entered into an option and license agreement aimed at developing and commercializing BITT’s innovative tumor necrosis factor (TNF) receptor 2 (TNFR2) antagonist antibodies. BeiGene has secured an option to an exclusive license to develop, manufacture, and commercialize BITT’s proprietary TNFR2 antagonist antibodies in Asia (excluding Japan), Australia, and New Zealand. The companies plan to conduct Phase 1 clinical trials of BITR2101, BITT’s lead TNFR2 antagonist antibody, including planned combination studies with tislelizumab, BeiGene’s anti-PD-1 antibody.…　続きを読む